Available from stock

Fulvestrant

SKU: F0328

Category: Steroids

Synonyms: ICI 182780 , Faslodex , 7alpha-[9-[(RS)-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17beta-diol; 129453-61-8
CAS-Number: C₃₂H₄₇F₅O₃S
Molecular Formula: 606.77
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White or off white crystalline powder
Identity: 1H-NMR

Properties

Solvents: DMSO (20 mg/ml), DMF (20 mg/ml), ethanol (20 mg/ml)
Melting Point: 104-106°C
Boiling Point: 674.78° C at 760 mmHg
Refractive Index: 1.52 (Predicted)
Density: 1.20 g/cm3

Shipping: AMBIENT
Short Term Storage: +4°C
Long Term Storage: -20°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at -20°C.

Transportation: Not dangerous goods

Description: Fulvestrant is a selective estrogen receptor degrader (SERD) that downregulates and degrades estrogen receptor α (ERα). It reduces dimerization and nuclear localization of the estrogen receptor (ER). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant inhibits the growth of ER-positive MCF-7 human breast cancer cells but not ER-negative BT-20 cells when used at a concentration of 1 µg/ml. It also prevents tumor growth in MCF-7 and Br10 breast cancer mouse xenograft models when used at a single dose of 5 mg per animal. Fulvestrant is neuroprotective in vitro against neurotoxicity induced by glutamate- and amyloid-β (1-42) (Aβ42) in primary rat hippocampal cells. Formulations containing fulvestrant have been used in the treatment of estrogen-sensitive breast cancer.
Smiles: OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4O)=C1
InChi Key: VWUXBMIQPBEWFH-WCCTWKNTSA-N
References: (1) A.E Wakeling, et al., Cancer Res. 51, 3867 (1991) , (2) J.F. Robertson, Br. J. Cancer 85, 11 (2001) (Review) , (3) N. Bundred & A. Howell, Expert Rev. Anticancer Ther. 2, 151 (2002) (Review) , (4) C.K. Osborne, et al., Br. J. Cancer 90, S2 (2004) (Review) , (5) S. Kansra, et al., Mol. Cell Endocrinol. 239, 27 (2005) , (6) M. Dowsett, et al., Breast Cancer Res. Treat. 93, S11 (2005) (Review) , (7) L. Zhao, et al., J. Pharmacol. Exp. Ther. 319, 1124 (2006) , (8) P. Kabos & V.F. Borges, Expert Opin. Pharmacother. 11, 807 (2010) (Review) , (9) S.E. Wardell, et al., Biochem. Pharmacol. 82, 122 (2011)

Fulvestrant is a selective estrogen receptor degrader (SERD) that downregulates and degrades estrogen receptor α (ERα). It reduces dimerization and nuclear localization of the estrogen receptor (ER). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant inhibits the growth of ER-positive MCF-7 human breast cancer cells but not ER-negative BT-20 cells when used at a concentration of 1 µg/ml. It also prevents tumor growth in MCF-7 and Br10 breast cancer mouse xenograft models when used at a single dose of 5 mg per animal. Fulvestrant is neuroprotective in vitro against neurotoxicity induced by glutamate- and amyloid-β (1-42) (Aβ42) in primary rat hippocampal cells. Formulations containing fulvestrant have been used in the treatment of estrogen-sensitive breast cancer.

SKU: F0328 Category: Steroids

Additional information

Additional information

Synonyms	ICI 182780, Faslodex, 7alpha-[9-[(RS)-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17beta-diol
Purity	≥98% (HPLC)
Appearance	White or off white crystalline powder
CAS-Number	129453-61-8
Molecular Formula	C32H47F5O3S
Molecular Weight	606.77
Identity	1H-NMR
Solvents	DMSO (20 mg/ml), DMF (20 mg/ml), ethanol (20 mg/ml)
Melting Point	104-106°C
Boiling Point	674.78° C at 760 mmHg
Refractive Index	1.52 (Predicted)
Density	1.20 g/cm3
Smiles	OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4O)=C1
InChi Key	VWUXBMIQPBEWFH-WCCTWKNTSA-N
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at -20°C.
Transportation	Not dangerous goods
References	(1) A.E Wakeling, et al., Cancer Res. 51, 3867 (1991), (2) J.F. Robertson, Br. J. Cancer 85, 11 (2001) (Review), (3) N. Bundred & A. Howell, Expert Rev. Anticancer Ther. 2, 151 (2002) (Review), (4) C.K. Osborne, et al., Br. J. Cancer 90, S2 (2004) (Review), (5) S. Kansra, et al., Mol. Cell Endocrinol. 239, 27 (2005), (6) M. Dowsett, et al., Breast Cancer Res. Treat. 93, S11 (2005) (Review), (7) L. Zhao, et al., J. Pharmacol. Exp. Ther. 319, 1124 (2006), (8) P. Kabos & V.F. Borges, Expert Opin. Pharmacother. 11, 807 (2010) (Review), (9) S.E. Wardell, et al., Biochem. Pharmacol. 82, 122 (2011)
Quantity	25 mg, Bulk